Conch blowing may be more effective in easing sleep apnea symptoms than deep breathing exercises

Researchers from Jaipur found that blowing into a conch might be more effective in easing obstructive sleep apnea symptoms compared to deep breathing exercises. A six-month study of 30 participants found that conch-blowing reduced daytime sleepiness by 34% and improved oxygen levels in blood during sleep. The study suggests that conch-blowing strengthens the muscles of the upper airway, which often collapse during sleep in people with obstructive sleep apnea.

Researchers from Jaipur have found that blowing into a conch shell might be more effective in easing obstructive sleep apnea (OSA) symptoms compared to traditional deep breathing exercises. A six-month study involving 30 participants revealed that conch-blowing reduced daytime sleepiness by 34% and improved oxygen levels in blood during sleep. The study suggests that conch-blowing strengthens the muscles of the upper airway, which often collapse during sleep in people with OSA [1].

Conch-blowing involves inhaling deeply and then forcefully exhaling through the conch shell. This exercise creates strong vibrations and airflow resistance, which may help strengthen the throat and soft palate muscles. These muscles are critical for maintaining an open airway during sleep. The study, conducted by the Eternal Heart Care Centre and Research Institute, found that participants who practiced conch-blowing experienced fewer breathing problems at night and reported being more alert during the day [1].

The standard treatment for OSA is a continuous positive airway pressure (CPAP) machine, which keeps a patient’s airway open by blowing air through a mask all night. However, CPAP therapy can be uncomfortable and has high discontinuation rates. The conch-blowing method presents a low-cost, simple, and potentially more comfortable alternative to CPAP therapy. If further research confirms these findings, conch-blowing could significantly impact the $10+ billion global OSA market, which currently lacks effective pharmacological options [2].

Meanwhile, Incannex Healthcare (Nasdaq: IXHL) has reported promising Phase 2 trial results for IHL-42X, a drug designed to treat OSA. The trial demonstrated significant clinical efficacy with AHI reductions of up to 83% in the high-dose group and 79% in the low-dose group. Patient-reported outcomes were notably strong, with 57.6% of participants reporting improved OSA and 89.5% describing the improvements as meaningful. The drug showed statistically significant benefits in multiple endpoints, including oxygen desaturation, sleep quality, and fatigue reduction, while maintaining an excellent safety profile [2].

The combination of conch-blowing and IHL-42X could offer a more comprehensive approach to managing OSA symptoms. While conch-blowing addresses the physical strengthening of the airway muscles, IHL-42X targets the underlying physiological mechanisms of OSA. Further research and clinical trials are needed to fully understand the potential of these interventions and their combined effects.

References:
[1] https://www.thesun.co.uk/health/36232987/snorers-blow-conch-shell-breathing/
[2] https://www.stocktitan.net/news/IXHL/incannex-receives-positive-patient-reported-outcomes-and-compelling-snf40wlb3a92.html